A new year means a new Fierce Biotech Fundraising Tracker to record all the venture capital being funneled into the industry for 2024. We're bumping up our reporting criteria from last year's ...

President-elect Trump has nominated biotech investor Jim O’Neill for deputy secretary of the Health and Human Services department. The HHS deputy secretary oversees the day-to-day operations of ...

CRISPR Therapeutics partnered with big biotech player Vertex Pharmaceuticals on Casgevy, and the companies started rolling out the therapy this year. So far, 45 treatment centers have been ...

WASHINGTON — Legislation targeting Chinese biotechnology companies caused a ruckus early this year. None of that may matter if Congress doesn’t pass it in December. The BIOSECURE Act would ...

Novartis is paying $1 billion upfront for global rights to PTC Therapeutics’ midphase Huntington's disease program, helping the biotech bounce quickly back from disappointing data on another ...

Meet the beaten-down biotech that Wood loves and Wall Street says may soar more than 65% over the coming 12 months. First, though, let's delve a little farther into Cathie Wood's strategy.

Founded in 2020, the local biotech is working on gene therapies for neuromuscular diseases, which can interfere with a person’s muscles and nerves. These conditions are often inherited ...

As we step into the final month of the year, let's take a look at the biotech companies whose drugs are under regulatory review in the U.S., with crucial decisions expected in December.

Even as US and European pharma companies decouple other parts of their businesses – moving away from Chinese research and development providers and creating separate production facilities in China, ...

The integration of artificial intelligence (AI) in the biotech industry seems boundless. Its combination with CRISPR could be the one area where AI has the most potential. Nobel prize winner and ...